Cancer drug developer Galecto's Q3 net loss narrows to $3.1 mln

Reuters

2025/11/07

Cancer drug developer Galecto's Q3 net loss narrows to $3.1 mln

Overview

Galecto Q3 net loss narrows to $3.1 mln from $3.9 mln last year
Company's cash reserves expected to fund GB3226 preclinical development into 2026

Outlook

Company anticipates cash reserves will fund preclinical development into 2026
Galecto requires additional capital for future clinical development

Result Drivers

INCREASED R&D COSTS - R&D expenses rose due to higher chemistry, manufacturing, and control costs, and preclinical studies
DECREASED ADMIN COSTS - General and administrative expenses fell due to reduced personnel and legal costs

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Net Income		-$3.13 mln
Q3 Basic EPS		-$2.36
Q3 Operating Expenses		$3.16 mln
Q3 Operating Income		-$3.16 mln

Press Release: ID:nGNX47zpM6

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2581049566"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581049566\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581049566?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 06:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581049566","market":"fut","top_or_hot":-1,"title":"Cancer drug developer Galecto's Q3 net loss narrows to $3.1 mln","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Cancer drug developer Galecto's Q3 net loss narrows to $3.1 mln</title></head><body><p><span>Overview</span></p><ul><li><p>Galecto Q3 net loss narrows to $3.1 mln from $3.9 mln last year</p></li><li><p>Company's cash reserves expected to fund GB3226 preclinical development into 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company anticipates cash reserves will fund preclinical development into 2026</p></li><li><p>Galecto requires additional capital for future clinical development</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>INCREASED R&amp;D COSTS - R&amp;D expenses rose due to higher chemistry, manufacturing, and control costs, and preclinical studies</p></li><li><p>DECREASED ADMIN COSTS - General and administrative expenses fell due to reduced personnel and legal costs</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$3.13 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$2.36</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$3.16 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$3.16 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nGNX47zpM6</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cancer drug developer Galecto's Q3 net loss narrows to $3.1 mln</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCancer drug developer Galecto's Q3 net loss narrows to $3.1 mln\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-07 06:20</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Cancer drug developer Galecto's Q3 net loss narrows to $3.1 mln</title></head><body><p><span>Overview</span></p><ul><li><p>Galecto Q3 net loss narrows to $3.1 mln from $3.9 mln last year</p></li><li><p>Company's cash reserves expected to fund GB3226 preclinical development into 2026</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company anticipates cash reserves will fund preclinical development into 2026</p></li><li><p>Galecto requires additional capital for future clinical development</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>INCREASED R&amp;D COSTS - R&amp;D expenses rose due to higher chemistry, manufacturing, and control costs, and preclinical studies</p></li><li><p>DECREASED ADMIN COSTS - General and administrative expenses fell due to reduced personnel and legal costs</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$3.13 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$2.36</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$3.16 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$3.16 mln</p></td><td></td></tr></tbody></table><p>Press Release: <span>ID:nGNX47zpM6</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI1QM:1","article_id":"2581049566","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581049566","pubTimestamp":1762467601,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cancer drug developer Galecto's Q3 net loss narrows to $3.1 mlnOverviewGalecto Q3 net loss narrows to $3.1 mln from $3.9 mln last yearCompany's cash reserves expected to fund GB3226 preclinical develo","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","GLTO":"Galecto Inc."},"translate_title":"癌症药物开发商Galecto第三季度净亏损收窄至310万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLTO":0.9},"content_text":"Cancer drug developer Galecto's Q3 net loss narrows to $3.1 mlnOverviewGalecto Q3 net loss narrows to $3.1 mln from $3.9 mln last yearCompany's cash reserves expected to fund GB3226 preclinical development into 2026OutlookCompany anticipates cash reserves will fund preclinical development into 2026Galecto requires additional capital for future clinical developmentResult DriversINCREASED R&D COSTS - R&D expenses rose due to higher chemistry, manufacturing, and control costs, and preclinical studiesDECREASED ADMIN COSTS - General and administrative expenses fell due to reduced personnel and legal costsKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Net Income-$3.13 mlnQ3 Basic EPS-$2.36Q3 Operating Expenses$3.16 mlnQ3 Operating Income-$3.16 mlnPress Release: ID:nGNX47zpM6For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}